

By Senator Jones

34-00322-26

20261638__

A bill to be entitled

An act relating to prohibitions against discriminatory practices relating to 340B entities and 340B drugs; providing a short title; creating s. 499.061, F.S.; providing definitions; prohibiting drug manufacturers from engaging in certain acts relating to the acquisition of 340B drugs by and the delivery of such drugs to specified pharmacies; providing an exception; prohibiting drug manufacturers from interfering with pharmacies' rights to contract with 340B entities; providing that each commission of certain acts constitutes a violation of the Florida Deceptive and Unfair Trade Practices Act and subjects the violator to certain actions and penalties; providing construction and applicability; creating s. 626.8829, F.S.; providing definitions; prohibiting health insurance issuers, pharmacy benefit managers, and other third-party payors, and agents thereof, from engaging in certain discriminatory acts relating to reimbursement to 340B entities for 340B drugs; providing applicability; providing that each commission of certain acts constitutes a violation of the Florida Deceptive and Unfair Trade Practices Act and subjects the violator to certain actions and penalties; providing construction; creating ss. 627.64743, 627.65733, and 641.31543, F.S.; providing definitions; prohibiting individual health insurers, group, blanket, and franchise health insurers, and health maintenance organizations, respectively, and

34-00322-26

20261638__

pharmacy benefit managers on behalf of such insurers and health maintenance organizations, from engaging in certain discriminatory acts relating to reimbursement to 340B entities for 340B drugs; providing applicability; providing that each commission of certain acts constitutes a violation of the Florida Deceptive and Unfair Trade Practices Act and subjects the violator to certain actions and penalties; providing construction; providing an effective date.

Be It Enacted by the Legislature of the State of Florida:

Section 1. This act may be cited as the "Defending Affordable Prescription Drug Costs Act."

Section 2. Section 499.061, Florida Statutes, is created to read:

499.061 Prohibitions against manufacturers' discriminatory practices relating to 340B drugs and 340B entities.—

(1) As used in this section, the term:

(a) "340B drug" means a drug that has been subject to any offer for reduced prices by a manufacturer pursuant to 42 U.S.C. s. 256b and is purchased by a covered entity as defined in 42 U.S.C. s. 256b(a)(4).

(b) "340B entity" means an entity participating or authorized to participate in the 340B Drug Pricing Program, as described in 42 U.S.C. s. 256b, including its pharmacy, or any pharmacy contracted with the participating entity to dispense drugs purchased through the 340B Drug Pricing Program.

(2) A manufacturer may not:

34-00322-26

20261638__

(a) Deny, restrict, prohibit, or otherwise interfere with, directly or indirectly, the acquisition of a 340B drug by, or delivery of a 340B drug to, a pharmacy that is under contract with a 340B entity and is authorized under such contract to receive and dispense 340B drugs on behalf of the covered entity unless such receipt is prohibited by the United States Department of Health and Human Services; or

(b) Interfere with a pharmacy's right to contract with a 340B entity.

(3) The commission of any act prohibited by this section is a deceptive and unfair trade practice and constitutes a violation of the Florida Deceptive and Unfair Trade Practices Act under part II of chapter 501, and subjects the violator to all actions, including, but not limited to, investigative demands, remedies, and penalties, provided for in the Florida Deceptive and Unfair Trade Practices Act.

(4) This section may not be construed to be less restrictive than federal law for a person or entity to which this section applies. This section may not be construed to be in conflict with any of the following:

(a) Applicable federal law or regulations.

(b) Other laws of this state which are compatible with applicable federal law.

(5) Limited distribution of a drug that is subject to a risk evaluation and mitigation strategy under 21 U.S.C. s. 355-1 is not a violation of this section.

Section 3. Section 626.8829, Florida Statutes, is created to read:

626.8829 Reimbursement to 340B entities for 340B drugs.—

34-00322-26

20261638__

(1) As used in this section, the term:

(a) "340B drug" means a drug that has been subject to any offer for reduced prices by a manufacturer pursuant to 42 U.S.C. s. 256b and is purchased by a covered entity as defined in 42 U.S.C. s. 256b(a)(4).

(b) "340B entity" means an entity participating or authorized to participate in the 340B Drug Pricing Program, as described in 42 U.S.C. s. 256b, including its pharmacy, or any pharmacy contracted with the participating entity to dispense drugs purchased through the 340B Drug Pricing Program.

(c) "Health insurance issuer" means an entity subject to the insurance laws and regulations of this state, or subject to the jurisdiction of the Commissioner of Insurance Regulation, which contracts, offers to contract, or enters into an agreement to provide, deliver, arrange for, pay for, or reimburse any of the costs of health care services. The term includes an accident and sickness insurance company, a health maintenance organization, a preferred provider organization or any similar entity, or any other entity providing a plan of health insurance or health benefits.

(d) "Pharmacy" has the same meaning as in s. 465.003.

(2) With respect to reimbursement to a 340B entity for a 340B drug, a health insurance issuer, pharmacy benefit manager, or other third-party payor, or its agents, may not do any of the following:

(a) Reimburse the 340B entity for the 340B drug at a rate lower than that paid for the same drug to non-340B entities or to entities owned or operated by the pharmacy benefit manager on the basis that the claim is for a 340B drug.

34-00322-26

20261638__

117 (b) Impose any terms or conditions on the 340B entity which
118 differ from such terms or conditions applied to non-340B
119 entities on the basis that the entity participates in the 340B
120 Drug Pricing Program set forth in 42 U.S.C. s. 256b or that the
121 drug is a 340B drug, including, but not limited to, any of the
122 following terms or conditions:

123 1. Fees, charges, clawbacks, or other adjustments or
124 assessments. As used in this subparagraph, the term "other
125 adjustments" includes, but is not limited to, placing any
126 additional requirements, restrictions, or unnecessary burdens on
127 the 340B entity which result in administrative costs or fees to
128 the 340B entity and which are not placed on non-340B entities,
129 including affiliate pharmacies of the health insurance issuer,
130 pharmacy benefit manager, or other third-party payor.

131 2. Dispensing fees that are less than dispensing fees for
132 non-340B entities.

133 3. Restrictions or requirements regarding participation in
134 standard or preferred pharmacy networks.

135 4. Requirements relating to the frequency or scope of
136 audits of inventory management systems.

137 5. Requirements that a claim for a drug include any
138 identification, billing modifier, attestation, or other
139 indication that a drug is a 340B drug in order to be processed
140 or resubmitted unless it is required by the Centers for Medicare
141 and Medicaid Services or the Agency for Health Care
142 Administration for the administration of the Medicaid program.

143 6. Any other restrictions, conditions, practices, or
144 policies that are not imposed on non-340B entities.

145 (c) Require the 340B entity to reverse, resubmit, or

34-00322-26

20261638__

146 clarify a claim after the initial adjudication unless such
147 actions are in the normal course of pharmacy business and not
148 related to 340B drug pricing.

149 (d) Base an action or contract requirement solely on the
150 basis that the entity is a participant in the 340B Drug Pricing
151 Program in such a manner that prevents or interferes with any
152 patient's choice to receive such drugs from the 340B entity or
153 its contracted pharmacy, including the creation of a restriction
154 or additional charge on a patient who chooses to receive drugs
155 from a 340B entity or its contracted pharmacy through direct
156 dispensing, delivery, mail order, or administration of such
157 drugs, regardless of the type of insurance coverage or
158 medication. For purposes of this paragraph, it is considered a
159 prohibited practice that prevents or interferes with a patient's
160 choice to receive drugs from a 340B entity or its contracted
161 pharmacy if a health insurance issuer, pharmacy benefit manager,
162 or other third-party payor places any additional requirements,
163 restrictions, or unnecessary burdens on the 340B entity or its
164 contracted pharmacy beyond that of any other pharmacy dispensing
165 medications within the scope of general law, including, but not
166 limited to, requiring a claim for a drug to include any
167 identification, billing modifier, attestation, or other
168 indication that a drug is a 340B drug in order to be processed
169 or resubmitted, unless it is required by the Centers for
170 Medicare and Medicaid Services or the Agency for Health Care
171 Administration in administration of the Medicaid program.

172 (e) Require or compel the submission of ingredient costs or
173 pricing data pertaining to 340B drugs to any health insurance
174 issuer, pharmacy benefit manager, or other third-party payor.

34-00322-26

20261638__

175 (f) Exclude the 340B entity from the network of the health
176 insurance issuer, pharmacy benefit manager, or other third-party
177 payor on the basis that the 340B entity dispenses drugs subject
178 to an agreement under 42 U.S.C. s. 256b, or refuse to contract
179 with the 340B entity for reasons other than those that apply
180 equally to non-340B entities.

181 (3) Subsection (2) does not apply to the Medicaid program
182 as payor when Medicaid provides reimbursement for covered
183 outpatient drugs as defined in 42 U.S.C. s. 1396r-8(k).

184 (4) The commission of any act prohibited by this section is
185 a deceptive and unfair trade practice, constitutes a violation
186 of the Florida Deceptive and Unfair Trade Practices Act under
187 part II of chapter 501, and subjects the violator to all
188 actions, including, but not limited to, investigative demands,
189 remedies, and penalties, provided for in the Florida Deceptive
190 and Unfair Trade Practices Act.

191 (5) This section may not be construed to be less
192 restrictive than federal law for a person or entity to which
193 this section applies. This section may not be construed to be in
194 conflict with any of the following:

195 (a) Applicable federal law or regulations.

196 (b) Other laws of this state that are compatible with
197 applicable federal law.

198 (6) Limited distribution of a drug that is subject to a
199 risk evaluation and mitigation strategy under 21 U.S.C. s. 355-1
200 is not a violation of this section.

201 Section 4. Section 627.64743, Florida Statutes, is created
202 to read:

203 627.64743 Reimbursement to 340B entities for 340B drugs.—

34-00322-26

20261638__

(1) As used in this section, the term:

(a) "340B drug" means a drug that has been subject to any offer for reduced prices by a manufacturer pursuant to 42 U.S.C. s. 256b and is purchased by a covered entity as defined in 42 U.S.C. s. 256b(a)(4).

(b) "340B entity" means an entity participating or authorized to participate in the 340B Drug Pricing Program, as described in 42 U.S.C. s. 256b, including its pharmacy, or any pharmacy contracted with the participating entity to dispense drugs purchased through the 340B Drug Pricing Program.

(c) "Pharmacy" has the same meaning as in s. 465.003.

(d) "Pharmacy benefit manager" has the same meaning as in s. 627.64741(1).

(2) With respect to reimbursement to a 340B entity for a 340B drug, an insurer issuing, delivering, or renewing an individual health insurance policy in this state which provides prescription drug coverage, or a pharmacy benefit manager on behalf of such insurer, may not do any of the following:

(a) Reimburse the 340B entity for the 340B drug at a rate lower than that paid for the same drug to non-340B entities on the basis that the claim is for a 340B drug.

(b) Impose any terms or conditions on the 340B entity which differ from such terms or conditions applied to non-340B entities on the basis that the entity participates in the 340B Drug Pricing Program set forth in 42 U.S.C. s. 256b or that the drug is a 340B drug, including, but not limited to, any of the following terms or conditions:

1. Fees, charges, clawbacks, or other adjustments or assessments. As used in this subparagraph, the term "other

34-00322-26

20261638__

adjustments" includes, but is not limited to, placing any additional requirements, restrictions, or unnecessary burdens on the 340B entity which result in administrative costs or fees to the 340B entity and which are not placed on non-340B entities, including affiliate pharmacies or in-network pharmacies of the insurer or of the pharmacy benefit manager.

2. Dispensing fees that are less than dispensing fees for non-340B entities.

3. Restrictions or requirements regarding participation in standard or preferred pharmacy networks.

4. Requirements relating to the frequency or scope of audits of inventory management systems.

5. Requirements that a claim for a drug include any identification, billing modifier, attestation, or other indication that a drug is a 340B drug in order to be processed or resubmitted unless it is required by the Centers for Medicare and Medicaid Services or the Agency for Health Care Administration for the administration of the Medicaid program.

6. Any other restrictions, conditions, practices, or policies that are not imposed on non-340B entities.

(c) Require the 340B entity to reverse, resubmit, or clarify a claim after the initial adjudication unless such actions are in the normal course of pharmacy business and not related to 340B drug pricing.

(d) Base an action or a contract requirement solely on the basis that the entity is a participant in the 340B Drug Pricing Program in such a manner that prevents or interferes with a patient's choice to receive such drugs from the 340B entity or its contracted pharmacy, including the creation of a restriction

34-00322-26

20261638__

or an additional charge on a patient who chooses to receive drugs from a 340B entity or its contracted pharmacy through direct dispensing, delivery, mail order, or administration of such drugs, regardless of the type of insurance coverage or medication. For purposes of this paragraph, it is considered a prohibited practice that prevents or interferes with a patient's choice to receive drugs from a 340B entity or its contracted pharmacy if the insurer, or the pharmacy benefit manager on behalf of the insurer, places any additional requirements, restrictions, or unnecessary burdens on the 340B entity or its contracted pharmacy beyond that of any other pharmacy dispensing medications within the scope of general law, including, but not limited to, requiring a claim for a drug to include any identification, billing modifier, attestation, or other indication that a drug is a 340B drug in order to be processed or resubmitted, unless it is required by the Centers for Medicare and Medicaid Services or the Agency for Health Care Administration in administration of the Medicaid program.

(e) Require or compel the submission of ingredient costs or pricing data pertaining to 340B drugs to the insurer or the pharmacy benefit manager.

(f) Exclude the 340B entity from the network of the insurer or pharmacy benefit manager on the basis that the 340B entity dispenses drugs subject to an agreement under 42 U.S.C. s. 256b, or refuse to contract with the 340B entity for reasons other than those that apply equally to non-340B entities.

(3) Subsection (2) does not apply to the Medicaid program as payor when Medicaid provides reimbursement for covered outpatient drugs as defined in 42 U.S.C. s. 1396r-8(k).

34-00322-26

20261638__

291 (4) The commission of any act prohibited by this section is
292 a deceptive and unfair trade practice, constitutes a violation
293 of the Florida Deceptive and Unfair Trade Practices Act under
294 part II of chapter 501, and subjects the violator to all
295 actions, including, but not limited to, investigative demands,
296 remedies, and penalties, provided for in the Florida Deceptive
297 and Unfair Trade Practices Act. Each commission of a prohibited
298 act constitutes a violation of the Florida Deceptive and Unfair
299 Trade Practices Act.

300 (5) This section may not be construed to be less
301 restrictive than federal law for a person or entity to which
302 this section applies. This section may not be construed to be in
303 conflict with any of the following:

304 (a) Applicable federal law or federal regulations.

305 (b) Other laws of this state that are compatible with
306 applicable federal law.

307 (6) Limited distribution of a drug that is subject to a
308 risk evaluation and mitigation strategy under 21 U.S.C. s. 355-1
309 is not a violation of this section.

310 Section 5. Section 627.65733, Florida Statutes, is created
311 to read:

312 627.65733 Reimbursement to 340B entities for 340B drugs.—

313 (1) As used in this section, the term:

314 (a) "340B drug" means a drug that has been subject to any
315 offer for reduced prices by a manufacturer pursuant to 42 U.S.C.
316 s. 256b and is purchased by a covered entity as defined in 42
317 U.S.C. s. 256b(a) (4).

318 (b) "340B entity" means an entity participating or
319 authorized to participate in the 340B Drug Pricing Program, as

34-00322-26

20261638__

described in 42 U.S.C. s. 256b, including its pharmacy, or any pharmacy contracted with the participating entity to dispense drugs purchased through the 340B Drug Pricing Program.

(c) "Pharmacy" has the same meaning as in s. 465.003.

(d) "Pharmacy benefit manager" has the same meaning as in s. 627.6572(1).

(2) With respect to reimbursement to a 340B entity for 340B drugs, an insurer issuing, delivering, or renewing a group, blanket, or franchise health insurance policy in this state which provides prescription drug coverage, or a pharmacy benefit manager on behalf of such insurer, may not do any of the following:

(a) Reimburse the 340B entity for 340B drugs at a rate lower than that paid for the same drug to non-340B entities on the basis that the claim is for a 340B drug.

(b) Impose any terms or conditions on the 340B entity which differ from such terms or conditions applied to non-340B entities on the basis that the entity participates in the 340B Drug Pricing Program set forth in 42 U.S.C. s. 256b or that a drug is a 340B drug, including, but not limited to, any of the following terms or conditions:

1. Fees, charges, clawbacks, or other adjustments or assessments. As used in this subparagraph, the term "other adjustments" includes, but is not limited to, placing any additional requirements, restrictions, or unnecessary burdens on the 340B entity which result in administrative costs or fees to the 340B entity and which are not placed on non-340B entities, including affiliate pharmacies or in-network pharmacies of the insurer or of the pharmacy benefit manager.

34-00322-26

20261638__

349 2. Dispensing fees that are less than dispensing fees for
350 non-340B entities.

351 3. Restrictions or requirements regarding participation in
352 standard or preferred pharmacy networks.

353 4. Requirements relating to the frequency or scope of
354 audits of inventory management systems.

355 5. Requirements that a claim for a drug include any
356 identification, billing modifier, attestation, or other
357 indication that a drug is a 340B drug in order to be processed
358 or resubmitted unless it is required by the Centers for Medicare
359 and Medicaid Services or the Agency for Health Care
360 Administration for the administration of the Medicaid program.

361 6. Any other restrictions, conditions, practices, or
362 policies that are not imposed on non-340B entities.

363 (c) Require the 340B entity to reverse, resubmit, or
364 clarify a claim after the initial adjudication unless such
365 actions are in the normal course of pharmacy business and not
366 related to 340B drug pricing.

367 (d) Base an action or contract requirement solely on the
368 basis that the entity is a participant in the 340B Drug Pricing
369 Program in such a manner that prevents or interferes with any
370 patient's choice to receive such drugs from the 340B entity or
371 its contracted pharmacy, including the creation of a restriction
372 or additional charge on a patient who chooses to receive drugs
373 from a 340B entity or its contracted pharmacy through direct
374 dispensing, delivery, mail order, or administration of such
375 drugs, regardless of the type of insurance coverage or
376 medication. For purposes of this paragraph, it is considered a
377 prohibited practice that prevents or interferes with a patient's

34-00322-26

20261638__

choice to receive drugs from a 340B entity or its contracted pharmacy if the insurer, or the pharmacy benefit manager on behalf of the insurer, places any additional requirements, restrictions, or unnecessary burdens on the 340B entity beyond that of any other pharmacy dispensing medications within the scope of general law, including, but not limited to, requiring a claim for a drug to include any identification, billing modifier, attestation, or other indication that a drug is a 340B drug in order to be processed or resubmitted, unless it is required by the Centers for Medicare and Medicaid Services or the Agency for Health Care Administration in administration of the Medicaid program.

(e) Require or compel the submission of ingredient costs or pricing data pertaining to 340B drugs to the insurer or the pharmacy benefit manager.

(f) Exclude the 340B entity from the network of the insurer or pharmacy benefit manager on the basis that the 340B entity dispenses drugs subject to an agreement under 42 U.S.C. s. 256b, or refuse to contract with the 340B entity for reasons other than those that apply equally to non-340B entities.

(3) Subsection (2) does not apply to the Medicaid program as payor when Medicaid provides reimbursement for covered outpatient drugs as defined in 42 U.S.C. s. 1396r-8(k).

(4) The commission of any act prohibited by this section is a deceptive and unfair trade practice, constitutes a violation of the Florida Deceptive and Unfair Trade Practices Act under part II of chapter 501, and subjects the violator to all actions, including, but not limited to, investigative demands, remedies, and penalties, provided for in the Florida Deceptive

34-00322-26

20261638__

and Unfair Trade Practices Act. Each commission of a prohibited act constitutes a violation of the Florida Deceptive and Unfair Trade Practices Act.

(5) This section may not be construed to be less restrictive than federal law for a person or entity to which this section applies. This section may not be construed to be in conflict with any of the following:

(a) Applicable federal law or regulations.

(b) Other laws of this state that are compatible with applicable federal law.

(6) Limited distribution of a drug that is subject to a risk evaluation and mitigation strategy under 21 U.S.C. s. 355-1 is not a violation of this section.

Section 6. Section 641.31543, Florida Statutes, is created to read:

641.31543 Reimbursement to 340B entities for 340B drugs.—

(1) As used in this section, the term:

(a) "340B drug" means a drug that has been subject to any offer for reduced prices by a manufacturer pursuant to 42 U.S.C. s. 256b and is purchased by a covered entity as defined in 42 U.S.C. s. 256b(a)(4).

(b) "340B entity" means an entity participating or authorized to participate in the 340B Drug Pricing Program, as described in 42 U.S.C. s. 256b, including its pharmacy, or any pharmacy contracted with the participating entity to dispense drugs purchased through the 340B Drug Pricing Program.

(c) "Pharmacy" has the same meaning as in s. 465.003.

(d) "Pharmacy benefit manager" has the same meaning as in s. 641.314(1).

34-00322-26

20261638__

436 (2) With respect to reimbursement to a 340B entity for a
437 340B drug, a health maintenance organization issuing,
438 delivering, or renewing a health maintenance contract in this
439 state which provides prescription drug coverage, or a pharmacy
440 benefit manager on behalf of such health maintenance
441 organization, may not do any of the following:

442 (a) Reimburse the 340B entity for the 340B drug at a rate
443 lower than that paid for the same drug to non-340B entities on
444 the basis that the claim is for a 340B drug.

445 (b) Impose any terms or conditions on the 340B entity which
446 differ from such terms or conditions applied to non-340B
447 entities on the basis that the entity participates in the 340B
448 Drug Pricing Program set forth in 42 U.S.C. s. 256b or that a
449 drug is a 340B drug, including, but not limited to, any of the
450 following terms or conditions:

451 1. Fees, charges, clawbacks, or other adjustments or
452 assessments. For purposes of this subparagraph, the term "other
453 adjustments" includes, but is not limited to, placing any
454 additional requirements, restrictions, or unnecessary burdens on
455 the 340B entity which result in administrative costs or fees to
456 the 340B entity which are not placed on non-340B entities,
457 including affiliate pharmacies or in-network pharmacies of the
458 health maintenance organization or of the pharmacy benefit
459 manager.

460 2. Dispensing of fees that are less than dispensing fees
461 for non-340B entities.

462 3. Restrictions or requirements regarding participation in
463 standard or preferred pharmacy networks.

464 4. Requirements relating to the frequency or scope of

34-00322-26

20261638__

audits of inventory management systems.

5. Requirements that a claim for a drug include any identification, billing modifier, attestation, or other indication that a drug is a 340B drug in order to be processed or resubmitted unless it is required by the Centers for Medicare and Medicaid Services or the Agency for Health Care Administration for the administration of the Medicaid program.

6. Any other restrictions, conditions, practices, or policies that are not imposed on non-340B entities.

(c) Require the 340B entity to reverse, resubmit, or clarify a claim after the initial adjudication unless such actions are in the normal course of pharmacy business and not related to 340B drug pricing.

(d) Base an action or contract requirement solely on the basis that the entity is a participant in the 340B Drug Pricing Program in such a manner that prevents or interferes with any patient's choice to receive such drugs from the 340B entity or its contracted pharmacy, including the creation of a restriction or additional charge on a patient who chooses to receive drugs from a 340B entity or its contracted pharmacy through direct dispensing, delivery, mail order, or administration of such drugs, regardless of the type of insurance coverage or medication. For purposes of this paragraph, it is considered a prohibited practice that prevents or interferes with a patient's choice to receive drugs from a 340B entity or its contracted pharmacy if the health maintenance organization, or the pharmacy benefit manager on behalf of the health maintenance organization, places any additional requirements, restrictions, or unnecessary burdens on the 340B entity or its contracted

34-00322-26

20261638__

pharmacy beyond that of any other pharmacy dispensing medications within the scope of general law, including, but not limited to, requiring a claim for a drug to include any identification, billing modifier, attestation, or other indication that a drug is a 340B drug in order to be processed or resubmitted, unless it is required by the Centers for Medicare and Medicaid Services or the Agency for Health Care Administration in administration of the Medicaid program.

(e) Require or compel the submission of ingredient costs or pricing data pertaining to 340B drugs to the health maintenance organization or the pharmacy benefit manager.

(f) Exclude the 340B entity from the network of the health maintenance organization or pharmacy benefit manager on the basis that the 340B entity dispenses drugs subject to an agreement under 42 U.S.C. s. 256b, or refuse to contract with the 340B entity for reasons other than those that apply equally to non-340B entities.

(3) Subsection (2) does not apply to the Medicaid program as payor when Medicaid provides reimbursement for covered outpatient drugs as defined in 42 U.S.C. s. 1396r-8(k).

(4) The commission of any act prohibited by this section is a deceptive and unfair trade practice, constitutes a violation of the Florida Deceptive and Unfair Trade Practices Act under part II of chapter 501, and subjects the violator to all actions, including, but not limited to, investigative demands, remedies, and penalties, provided for in the Florida Deceptive and Unfair Trade Practices Act. Each commission of a prohibited act constitutes a violation of the Florida Deceptive and Unfair Trade Practices Act.

34-00322-26

20261638__

(5) This section may not be construed to be less restrictive than federal law for a person or entity to which this section applies. This section may not be construed to be in conflict with any of the following:

(a) Applicable federal law or regulations.

(b) Other laws of this state that are compatible with applicable federal law.

(6) Limited distribution of a drug that is subject to a risk evaluation and mitigation strategy under 21 U.S.C. s. 355-1 is not a violation of this section.

Section 7. This act shall take effect July 1, 2026.